BackCalliditas Therapeutics AB (publ) Overview

Calliditas Therapeutics AB (publ) EBIT

Track Calliditas Therapeutics AB (publ)'s EBIT ($-56M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$4.12M
↓ 222.48% YoY

As of Aug 31, 2026

Annual EBIT (TTM)

-$55.66M
↓ 2544.88% YoY

Trailing 12 months ending Aug 31, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Calliditas Therapeutics AB (publ) (CALTX.ST) FAQ

The latest EBIT for CALTX.ST is $-56M as of August 2026. That compares with $-2.1M in the prior-year period — down 2544.9% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Calliditas Therapeutics AB (publ)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, CALTX.ST's EBIT moved from $-2.1M to $-56M — a 2544.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Calliditas Therapeutics AB (publ)'s operating scale or balance-sheet position.

Against Healthcare companies, CALTX.ST currently prints $-56M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Calliditas Therapeutics AB (publ)'s growth, margins, and balance sheet.

A EBIT figure of $-56M for CALTX.ST is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting CALTX.ST's EBIT ($-56M), review year-over-year change from $-2.1M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.